Pharscin Pharma: Injectable Sulbactam-Nafcillin has received drug re-registration approvalZhitong·Oct 29, 2025 at 03:06 AM002907+2.41%
Pharscin Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 72.4556 million yuan, a year-on-year decrease of 2.84%Zhitong·Oct 28, 2025 at 05:19 AM002907+2.41%
Pharscin Pharma: Crizotinib capsules are expected to be launched for sale by the end of next yearZhitong·Oct 23, 2025 at 03:26 AM002907+2.41%
Pharscin Pharma obtained the drug registration certificate for Crizotinib capsulesZhitong·Oct 20, 2025 at 04:43 AM002907+2.41%
Pharscin Pharma's controlling shareholder's concerted action parties plan to reduce their holdings by no more than 3%Zhitong·Oct 14, 2025 at 08:33 AM002907+2.41%
Pharscin Pharma: The company has received the drug re-registration approval noticeZhitong·Sep 29, 2025 at 04:14 AM002907+2.41%
Pharscin Pharma: The company has become the holder of the marketing authorization for the Jian'er Xiaoshi oral liquid medicationZhitong·Sep 5, 2025 at 04:14 AM002907+2.41%
Pharscin Pharma: Chengdu Dijiang 3.00% reduction completedZhitong·Jul 30, 2025 at 04:38 AM002907+2.41%
Pharscin Pharma: Company drug production license change and passing GMP compliance inspectionZhitong·Jul 25, 2025 at 04:39 AM002907+2.41%
Pharscin Pharma: Received the drug re-registration approval noticeZhitong·Jul 21, 2025 at 03:48 AM002907+2.41%
Pharscin Pharma: Cang Er Zi Nasal Inflammation Capsules have completed domestic drug filingZhitong·Jul 7, 2025 at 04:38 AM002907+2.41%
Pharscin Pharma: CX001 sustained-release tablets have received approval for clinical trialsZhitong·Jul 2, 2025 at 03:48 AM002907+2.41%
Pharmaceutical stocks surge, Pharscin Pharma and GLORIA PHARMA hit the limit upZhitong·May 26, 2025 at 08:51 PM002907+2.41%002437+0.35%
Pharscin Pharma's controlling shareholders and executives plan to reduce their holdings by no more than 4.1803 million sharesZhitong·May 13, 2025 at 07:51 AM002907+2.41%
